5-Year Financial Performance & Trend Analysis
This analysis synthesizes information from Oceania Healthcare's 2022 and 2024 Annual Reports to provide a five-year perspective (FY2020-FY2024). Oceania has undergone significant strategic evolution, focusing on premiumisation, portfolio optimisation through development (shifting from brownfield to greenfield) and divestments, and enhancing resident experience. Operationally, Underlying EBITDA shows a general upward trend, demonstrating core business resilience despite challenges like COVID-19 and sector cost pressures. However, reported profitability (NPAT) has been highly volatile, heavily influenced by significant swings in property valuations. Operating cash flow has also varied but showed strength in FY24. Debt levels increased substantially to fund development but are now a focus for reduction, supported by recent refinancing. Key strengths include a strong market position in a growing sector, a modernising portfolio, and innovation focus. Weaknesses include high debt levels (though managed within covenants), volatile reported profits, and the persistent discount of its share price to Net Tangible Assets (NTA).
Oceania's financial journey over the past five years reflects its strategic activities and the broader market environment. Underlying EBITDA, a measure stripping out property valuations and other non-operational items, has shown a generally positive trajectory, increasing from a proforma $65.6m in FY21 (12m equivalent from AR22 p20) to $82.6m in FY24. This indicates underlying operational improvements and contributions from new developments and acquisitions, despite headwinds like COVID-19 impacts (especially in FY21/FY22) and rising operating costs.
Reported Net Profit After Tax (NPAT) has fluctuated dramatically, highlighting the significant impact of property valuations inherent in the sector's accounting. FY20 saw a loss ($12.8m), FY21 (10 months) recorded a strong profit ($85.7m) driven by high valuation gains, FY22 saw profit moderate ($61.1m), FY23 dropped significantly ($15.4m) due to lower valuation gains, and FY24 rebounded ($31.5m) but remained below FY21/FY22 levels. Underlying NPAT provides a more stable view of operational profitability, growing from $43.7m in FY20 to $62.1m in FY24.
Operating Cash Flow was strong in FY20 ($98.4m), dipped slightly in the 10-month FY21 ($96.0m), peaked in FY22 ($105.5m), reduced in FY23 ($70.2m) potentially due to timing of development settlements or working capital movements, and recovered well in FY24 ($85.4m).
Note: FY2021 data covers a 10-month period due to a balance date change from May 31 to March 31. Proforma 12-month figures from the 2022 report are used where available for trend consistency but should be interpreted with caution.
| Metric ($NZm unless stated) | FY2020 (12m) | FY2021 (10m) | FY2022 (12m) | FY2023 (12m) | FY2024 (12m) |
|---|---|---|---|---|---|
| Underlying EBITDA | 64.3 | 56.0 | 76.2 | 80.0 | 82.6 |
| Underlying NPAT | 43.7 | 41.9 | 56.7 | 58.6 | 62.1 |
| Reported Profit/(Loss) for the Period | (12.8) | 85.7 | 61.1 | 15.4 | 31.5 |
| Total Comprehensive Income/(Loss) | 10.7 | 167.9 | 114.4 | 34.5 | 70.5 |
| Operating Cash Flow | 98.4 | 96.0 | 105.5 | 70.2 | 85.4 |
| Total Assets | 1,547.3 | 1,882.2 | 2,197.7 | 2,544.9 | 2,782.3 |
| Total Equity | 593.5 | 833.6 | 948.8 | 962.3 | 1,026.5 |
| Occupancy (%) | 91.5% | 92.4% | 92.0% | 90.4% | 91.1% |
Data sourced from 3-Year Summaries in 2022 (p36) and 2024 (p49) Annual Reports. FY2021 is a 10-month period. FY2020 Underlying NPAT restated per AR22 p36 footnote. Underlying EBITDA uses figures from AR24 p49 and AR22 p36 (FY20).
The financial year ended 31 March 2024 saw Oceania deliver favourable results compared to FY2023. Total Comprehensive Income more than doubled to $70.5m (+104.3%), driven by improved property valuations compared to the prior year and solid operating performance. Reported NPAT also doubled to $31.5m (+104.5%).
Operationally, Underlying NPAT grew 6.0% to $62.1m, and Underlying EBITDA increased 3.2% to $82.6m. This was supported by strong sales volumes (total sales up 16.7% to 476 units/suites) and improved operating cash flow, which rose 21.7% to $85.4m, reflecting increased receipts from Occupation Right Agreements (+26.6%). Occupancy also saw a slight improvement to 91.1% from 90.4% in FY23.
Total assets grew 9.3% to $2.8bn, largely due to continued development across 10 sites and valuation uplifts. Net assets increased 6.7% to $1.0bn. The company continued its divestment program, exiting or closing six sites during the period, receiving $21.0m in gross proceeds. Post balance date, further settlements and contracts progressed this strategy.
Despite the positive results, the Directors resolved not to pay a final dividend for FY2024, prioritizing capital retention for ongoing investment in growth and portfolio transformation, consistent with the interim dividend decision and the revised dividend policy (30-50% of Underlying NPAT payout ratio).
Oceania's debt levels increased significantly between FY20 and FY24, primarily to fund its extensive development program and acquisitions. Total borrowings (excluding capitalised costs) rose from under $330m pre-FY21 to $644m by March 2024 (AR24 p76). This includes bank facilities and retail bonds ($125m OCA010 due Oct 2027, $100m OCA020 due Sep 2028).
Key metrics as at 31 March 2024:
Commentary on Acceptability: A gearing ratio around 38% is relatively high compared to some conservative industrial companies but not unusual for property development entities, especially during active build phases. Peer retirement village operators in NZ also carry significant debt. The key factors are the ability to service the debt (interest cover) and the value of the underlying assets (LVR). Oceania has consistently met its covenants. The successful refinancing in March 2025 provides security over tenure. However, the company has explicitly stated a focus on reducing gearing (as seen in the HY25 results and dividend pause), indicating that management and likely the market view current levels as needing active management downwards, supported by asset sales and operational cash flow.
As at 31 March 2024, Oceania Healthcare had 724,154,779 ordinary shares issued (AR24 p74). Total contributed equity stood at $716.0m. Total Equity (including retained earnings/losses and reserves) was $1,026.5m.
Market Capitalisation vs NTA: A persistent theme has been the significant discount of Oceania's share price to its NTA per share. While NTA is largely based on independent property valuations, the market price reflects investor sentiment, profitability concerns, debt levels, dividend outlook, and sector risks. This discount suggests the market may be pricing in higher risk or lower future growth/profitability than implied by the asset valuations alone.
Comparing Oceania Healthcare to its main NZX-listed peers (Ryman Healthcare, Summerset Group, Arvida Group) provides valuable market context. Key areas for comparison typically include:
General Observations (Based on Historical Context): Historically, Oceania has often traded at a larger discount to NTA compared to Ryman and Summerset. Its gearing has sometimes been higher due to its development phasing. While all operators face similar sector trends (demographics, staffing costs), their specific strategies, portfolio maturity, and development pace differ, leading to varied financial outcomes and market valuations.
Over the past five years, Oceania Healthcare has actively reshaped its business, investing heavily in premium developments and acquisitions while starting to divest non-core assets. This strategy has grown the asset base significantly and aimed to enhance future earnings quality, reflected in the generally positive trend of Underlying EBITDA. However, this growth has come at the cost of increased debt and volatile reported profits due to property revaluations. The company's current focus is rightly on consolidating its position: accelerating sales, delivering its pipeline efficiently, optimising costs, and reducing debt gearing. Success in these areas, particularly in improving sell-down rates and managing operational costs effectively, will be crucial for improving profitability, restoring dividends, and potentially closing the valuation gap between its share price and NTA. The long-term demographic drivers remain favourable for the sector.